Picture [LSUS] – The Business Web Portal 650x65px
Document › Details

4SC AG. (1/21/11). "Press Release: 4SC Presents Update on Phase II SHELTER Trial with Oral Pan-HDAC Resminostat at the 2011 Gastrointestinal Cancer Symposium". Planegg-Martinsried.

Region Region San Francisco, CA
  Country United States (USA)
Organisation Organisation 4SC AG (FSE: VSC)
  Group 4SC (Group)
Products Product resminostat (4SC-201)
  Product 2 oncology
Person Person Bitzer, Michael (Univ Tübingen 201009 Professor Univ Hospital Tübingen)

4SC (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, will today present a poster update on the Phase II SHELTER trial in hepatocellular carcinoma (HCC) with the oral pan-histone deacetylase (HDAC) inhibitor resminostat. The poster will be presented by the lead investigator, Professor Dr. Michael Bitzer, at the 2011 Gastrointestinal Cancer Symposium (co-sponsored by the American Society of Clinical Oncology - ASCO, the American Society of Radiation Oncology - ASTRO and the Society of Surgical Oncology - SSO) on 20-21 January in San Francisco, USA.

Abstract: #71271:

Titel: Clinical update on the SHELTER study: A phase I/II trial of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC)

Session date and time: 21 January 2011, 11:45 am - 1.15 pm,

Poster Session
B: Pancreas, Small Bowel and Hepatobiliary Tract
Poster Presenter: M. Bitzer, M. Horger, T. Ganten, M.P.Ebert, M.A. Woerns,
M.M. Dollinger, A. Kirsch, G. Gerken, M.E. Scheulen, R. Jankowsky, A. Mais,
B. Hauns, B. Hentsch, U.M. Lauer

- Ends -

About Resminostat (4SC-201)

Resminostat (4SC-201) is an oral pan-histone-deacetylase (HDAC) inhibitor. HDAC inhibitors modify the DNA structure of tumour cells to cause their differentiation and programmed cell death (apoptosis) and are therefore considered to offer a mechanism of action that has the particular potential to halt tumour progression and induce tumour regression. Resminostat is currently also in a Phase II study as a second line treatment for advanced hepatocellular carcinoma and KRAS-mutant colorectal patients and as a third-line treatment in Hodgkin's lymphoma. In a completed Phase I trial in patients with various different cancer types, stable disease was achieved in over 50% of the patients, whilst the treatment was well tolerated and showed a positive, differentiating pharmacological profile to other drugs in this class.

About 4SC

4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a small molecule, is currently in Phase II development in rheumatoid arthritis and inflammatory bowel disease (IBD), for which positive results from a Phase IIa study were recently reported. The company's lead oncology compound, resminostat (4SC-201), a pan-histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma, Hodgkin's lymphoma and KRAS-mutant colorectal cancer. Two further oncology compounds, 4SC-203 and 4SC-205, are in Phase I studies. 4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.

Founded in 1997, 4SC has 94 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

For further information, please visit

For more information please contact:

Yvonne Alexander
Investor & Public Relations
Tel.: +49 (0) 89 70 07 63 - 66

MC Services (Europe)
Raimund Gabriel
Tel.: +49 (0) 89 21 02 28 - 30

The Trout Group (USA)
Chad Rubin
Tel.: +1 646 378 2947

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

Record changed: 2017-04-02


Picture [LSUS] – The Business Web Portal 650x65px

More documents for 4SC (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [LSA] – The Business Web Portal 650x89px

» top